IL6R and Castleman disease: Therapeutic targeting of IL-6 in chronic inflammatory diseases mainly relies on the two IL-6R antibodies tocilizumab and sarilumab, while the siltuximab directed against IL-6 has been approved for Castleman’s disease (39).